drugset / Trial / NCT02682498

Comparing Post-Op Narcotic Usage in Patients Receiving Periarticular Exparel vs. Standard Periarticular Joint Inj

NCT02682498

Phase 4 Completed 38 enrolled University of California, Irvine
RandomizedParallel-groupDouble-blindTreatment

Summary

This study seeks to determine whether a new sustained-release local anesthetic solution (Exparel - Liposomal Bupivacaine) injected into the soft tissues around the joint after surgery will decrease opioid consumption and adverse events in opioid-tolerant patients presenting for total knee arthroplasty. The research hypothesis is that the Exparel (study) group will use less opioid in the first 48 hours post-operatively than the control group.

Timeline

Start
2013-10
Primary completion
2015-07
Completion
2015-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified Other
Comparator Clonidine Other / unclassified 80 ug Other
Comparator Epinephrine Other / unclassified 0.5 mg Other
Comparator Ketorolac Other / unclassified 30 mg Other
Comparator Ropivacaine Other / unclassified 246.25 mg Other

Indications